Atrial fibrillation is one of the most common cardiac arrhythmias nurses encounter, and understanding its management is essential for safe patient care. In this episode, we break down what atrial fibrillation is, why it increases stroke risk, and how treatment strategies focus on rate control, rhythm control, and anticoagulation. We’ll review common medications, monitoring priorities, and key assessment findings you should never ignore.
Your support helps me provide more free resources like this! Consider supporting and getting more amazing pharmacology content! Head on over to meded101.com/nurse
Hypertension medications are a cornerstone of nursing practice, and understanding how they work can dramatically improve patient safety and outcomes. In this episode, we break down the major antihypertensive drug classes, including ACE inhibitors, ARBs, beta blockers, calcium channel blockers, and diuretics, in a practical and easy-to-understand way. You’ll learn how each class lowers blood pressure, key monitoring parameters, common side effects, and important nursing considerations. We’ll also cover when to hold medications, what lab values matter most, and how to educate patients to improve adherence.
Your support helps me provide more free resources like this! Consider supporting and getting more amazing pharmacology content! Head on over to meded101.com/nurse
Welcome to today’s episode, where we dive into two cornerstone classes of antihypertensives: ACE inhibitors and calcium channel blockers. These drugs are among the most frequently prescribed agents in both primary care and specialty settings, making a solid understanding of their practical nuances essential for clinicians, pharmacists, and learners alike. In this episode, we’ll break down the most important clinical pearls that can immediately improve your prescribing confidence and patient care.
We’ll start with ACE inhibitors, a class often selected for patients with hypertension, heart failure, diabetes, and chronic kidney disease. While widely effective, ACE inhibitors come with monitoring requirements and predictable side effect profiles that clinicians must recognize early. We’ll highlight what changes in renal function are acceptable, how to navigate issues like hyperkalemia and cough, and when switching to an ARB may be the safest option.
Next, we’ll move into calcium channel blockers, emphasizing the differences between dihydropyridines and non-dihydropyridines—two groups with distinct effects and unique considerations. I outline amlodipine’s adverse effects and how to navigate a patient who is experiencing edema.
By the end of this episode, you’ll walk away with a set of high-yield, easy-to-apply pearls that you can use in your next patient encounter. If you use antihypertensives and treat hypertension, heart failure, arrhythmias, or chronic kidney disease, this episode will help sharpen your understanding of these foundational therapies and elevate your medication management strategies. Let’s get started.
Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
The extended-release formulation of nifedipine provides more stable plasma concentrations and is preferred for chronic management of hypertension and angina.
Common adverse effects include headache, flushing, peripheral edema, and dizziness, all related to its vasodilatory action.
Nifedipine undergoes extensive first-pass metabolism in the liver, primarily via CYP3A4 enzymes, which significantly influences its bioavailability and potential drug interactions.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) can increase plasma levels of nifedipine, raising the risk of hypotension and adverse effects.
On this episode of the Real Life Pharmacology Podcast, I discuss amlodipine pharmacology, adverse effects, and important drug interactions.
I break down why edema occurs with amlodipine on this episode of the Real Life Pharmacology podcast.
While beta-blockers are typically the first-line agent for the prevention of chronic angina symptoms, CCBs like amlodipine can be used as an alternative.
There are some potential CYP3A4 interactions with amlodipine. I discuss the severity of these interactions and how to monitor patients.
